je.st
news
Tag: therapeutics
Halozyme Therapeutics: Even After Doubling, Shares Have Upside
2015-06-03 17:10:52| Biotech - Topix.net
The rally has been powered by myriad positive catalysts including positive trials and collaboration deals with other players in the biotech space. It has been quite a while since I provided an update on one of my favorite biotech stocks, Halozyme Therapeutics .
Tags: have
shares
upside
doubling
Sarepta Therapeutics Announces Plans To Submit Rolling NDA For Eteplirsen Following Today's Pre-NDA Meeting With The FDA
2015-06-03 06:47:48| drugdiscoveryonline Home Page
Sarepta Therapeutics, Inc., a developer of innovative RNA-targeted therapeutics, recently announced that the Company held a pre-New Drug Application (NDA) meeting with the U.S
Monday Morning Pre-Market Insights: Celldex Therapeutics, Celladon Corp, CTI BioPharma Corp, TG ...
2015-06-02 11:00:25| Trucking - Topix.net
Celldex Therapeutics, Inc. shares rose more than +10% in pre-market trading to $32.01 after the biopharmaceutical company released data on a study indicating that an experimental vaccine was effective in patients with brain cancer. The 12-month consensus target price on TipRanks for Celldex is $37.23, marking a 29% potential upside based on current levels.
Tags: monday
morning
corp
insights
Mirati Therapeutics presents preliminary results of MGCD265 tyrosine kinase inhibitor at ASCO 2015
2015-06-01 12:09:35| Logistics - Topix.net
Mirati Therapeutics, Inc. today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology Annual Meeting being held in Chicago from May 29-June 2, 2015. The Company also provided updates on its other targeted tyrosine kinase inhibitor, MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat.
Tags: results
presents
preliminary
inhibitor
TG Therapeutics, Inc. Announces Presentations of Its Proprietary...
2015-05-31 18:38:42| Logistics - Topix.net
TG Therapeutics, Inc. Announces Presentations of Its Proprietary Combination of TG-1101 Plus TGR-1202 as Well as TGR-1202 as a Single Agent in Ongoing Phase I/Ib Dose Escalation Clinical Studies Triple therapy cohort of the combination study to be presented separately as an oral presentation tomorrow morning, Monday, June 1st, 2015, at 51st American Society of Clinical Oncology Annual Meeting Data from both studies continues to demonstrate a favorable safety profile with a high level of activity and a significant dose-response relationship observed 85% CLL/SLL patients treated at the higher doses of 1202 as a single agent and in combination with TG-1101 achieved a nodal response, with most CLL patients achieving a Partial Response per iwCLL criteria with patients on study pending further assessment 50% Overall Response Rate in Follicular Lymphoma patients treated with the higher doses of ... (more)
Tags: presentations
announces
proprietary
therapeutics
Sites : [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] next »